tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pemphigus, Benign Familial D016506 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Critical Illness D016638 13 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Garcia-Criado FJ et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. 1997 Transplantation pmid:9293871
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Pascual J et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. 2006 Transplantation pmid:16861942
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Sheikh AM et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. 1999 Transplantation pmid:10440408
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. 1997 Transplantation pmid:9326428
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Tze WJ et al. In vitro effects of FK-506 on human and rat islets. 1990 Transplantation pmid:1694319
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Tsuchiya T et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. 2013 Transplantation pmid:23792649
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Hoogtanders K et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. 2007 Transplantation pmid:17264824
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Roberts CA et al. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. 2002 Transplantation pmid:12364862
Vincenti F et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. 2002 Transplantation pmid:11907427
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241